검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-CLL1 CART cells (Anti-CLL1 CART cells) 920th Hospital of Joint Logistics …·Acute Myeloid Leukemia 2 trials |
|---|---|
Overview Program | Anti-CLL1 CART cells |
Overview Company | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China |
Overview Modality | CGT |
Overview Target | Acute Myeloid Leukemia |
Overview Indication | Acute Myeloid Leukemia |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Toxicology Major finding | Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis.. C-type lectin-like molecule-1 (CLL1) is preferentially expressed on acute myeloid leukemia (AML) stem cells and AML blasts, which can be considered as AML-associated antigen. Anti-CLL1-based CAR-T cells exhibited effective tumor-k… |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 4 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 5월 22일 (53일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-CLL1 CART cells (Anti-CLL1 CART cells) 920th Hospital of Joint Logistics …·Acute Myeloid Leukemia 2 trials |
|---|---|
Overview Program | Anti-CLL1 CART cells |
Overview Company | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China |
Overview Modality | CGT |
Overview Target | Acute Myeloid Leukemia |
Overview Indication | Acute Myeloid Leukemia |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Toxicology Major finding | Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis.. C-type lectin-like molecule-1 (CLL1) is preferentially expressed on acute myeloid leukemia (AML) stem cells and AML blasts, which can be considered as AML-associated antigen. Anti-CLL1-based CAR-T cells exhibited effective tumor-k… |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 4 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 5월 22일 (53일 전 · 갱신 권장) |
추천 비교
추천 비교